Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fulcrum Therapeutics (FULC) Revenue (2020 - 2024)

Fulcrum Therapeutics (FULC) has disclosed Revenue for 5 consecutive years, with $80.0 million as the latest value for Q2 2024.

  • On a quarterly basis, Revenue rose 8990.91% to $80.0 million in Q2 2024 year-over-year; TTM through Mar 2025 was $80.0 million, a 3087.25% increase, with the full-year FY2024 number at $80.0 million, up 2752.05% from a year prior.
  • Revenue was $80.0 million for Q2 2024 at Fulcrum Therapeutics, up from $871000.0 in the prior quarter.
  • In the past five years, Revenue ranged from a high of $80.0 million in Q2 2024 to a low of $295000.0 in Q1 2023.
  • A 5-year average of $6.9 million and a median of $1.9 million in 2022 define the central range for Revenue.
  • Peak YoY movement for Revenue: crashed 88.62% in 2023, then soared 8990.91% in 2024.
  • Fulcrum Therapeutics' Revenue stood at $4.2 million in 2020, then rose by 19.72% to $5.1 million in 2021, then plummeted by 86.46% to $685000.0 in 2022, then increased by 27.15% to $871000.0 in 2023, then skyrocketed by 9084.85% to $80.0 million in 2024.
  • Per Business Quant, the three most recent readings for FULC's Revenue are $80.0 million (Q2 2024), $871000.0 (Q4 2023), and $759000.0 (Q3 2023).